Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial

• Main Authors: Yan-Fei Wu (Author), Ming-Wei Wei (Author), Rui-Jie Wang (Author), Xi-Ling Guo (Author), Hong-Xing Pan (Author), Ya-Chun Gao (Author), Xiao-Long Li (Author), Xue Wang (Author), Xiao-Min Ma (Author), Peng Wan (Author), Li Zhou (Author), Ya-Wen Zhu (Author), Jing-Xin Li (Author), Feng-Cai Zhu (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background The certification of immunogenicity consistency at different production scales is indispensable for the quality control of vaccines. Research design and methods A randomized, double-blind immunobridging trial in healthy adults aged 18-59 was divided into Scale A (50 L and 800 L) and Scale...